GlassScriptPhysician profile
Sarah B Vogelfanger
NPI 1356850283
$93,632.00
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $27K · 2023: $22K · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $9,642 · Travel and Lodging: $1,517 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,375.00 |
| Food and Beverage | $9,642.15 |
| Travel and Lodging | $1,517.07 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,750.80 | 2021-2025 | |
| Allergan, INC. | $1,925.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,388.60 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,263.78 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,031.47 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $903.10 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $780.97 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $698.92 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $605.10 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $579.48 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $554.06 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $435.99 | 2021-2024 | Trintellix |
| Tris Pharma INC | $335.79 | 2021-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $209.10 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $197.42 | 2024-2025 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $195.79 | 2021-2025 | Austedo Xr, Uzedy |
| Merck Sharp & Dohme LLC | $154.20 | 2021-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $139.33 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $129.66 | 2021-2025 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $123.20 | 2021-2022 | |
| Indivior INC. | $75.57 | 2021-2023 | Perseris |
| Corium, LLC | $57.74 | 2022-2025 | Azstarys |
| Adlon Therapeutics L.P. | $22.31 | 2021 | |
| Acadia Pharmaceuticals INC | $19.04 | 2025 | Nuplazid |
| Neuronetics, INC. | $18.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.32 | 2024 | Quviviq |
| Alfasigma USA, INC. | $13.17 | 2021 | |
| Noven Therapeutics, LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Vogelfanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.